-1920w%20(1).webp)
Age-related macular degeneration (AMD) is a progressive and serious eye disease that affects the retina, the light-sensitive tissue at the back of the eye that acts like a sensor to capture light and send visual signals to your brain. While AMD can manifest in different forms, nearly all cases start out as "dry" AMD. It begins when tiny, yellowish deposits of protein and lipid materials—known as drusen—build up underneath the retina in one or both eyes.
Because dry AMD develops gradually, it affects roughly 18 million people in the United States and approximately 200 million individuals globally. In its earliest stages, the condition is often quiet, but as the cellular layers beneath the retina break down over time, it begins to impair the clear, central vision you depend on every single day.
You may find straight lines appearing slightly wavy, struggle to recognize familiar faces, or notice that reading your phone, driving, or navigating dim rooms takes significantly more effort than it used to.
In the early stages, dry AMD is frequently asymptomatic, making routine comprehensive exams vital. As drusen accumulate and the disease advances, symptoms can include:
Table of Contents
Monday-Friday
8:00am-5:00pm
Table of Contents
469-505-2020
info@teceyecare.com
While the exact underlying trigger is still being researched, dry AMD develops as a progressive disease tied closely to the natural aging process. Key risk factors include advancing age, family history and genetics, smoking, race, cardiovascular disease, and obesity. Dry AMD progresses across three primary clinical stages:
● Early Stage: Small to medium-sized drusen spots appear on the back of one or both eyes, typically causing little to no noticeable vision change.
● Intermediate Stage: Drusen grow larger or multiply significantly. Patients often begin experiencing mild visual disturbances or trouble with dim environments.
● Advanced Stage (Geographic Atrophy): Retinal tissue gradually wears away and atrophies, causing permanent blind spots in your central field of view and potentially leading to legal blindness if left unmonitored.
For years, patients diagnosed with early to intermediate dry AMD had limited options beyond lifestyle adjustments, dietary modifications, and specific antioxidant vitamin regimens. Today, emerging technology has introduced non-invasive clinical therapies designed to manage the condition before advanced atrophy occurs:
● Photobiomodulation (Valeda™ Light Delivery System): An FDA-authorized, non-invasive light therapy utilizing specific wavelengths of visible and near-infrared light. Designed for patients with dry AMD characterized by intermediate-to-large drusen or non-central geographic atrophy, this therapeutic protocol works at a cellular level to help improve and maintain central visual acuity.
● Lifestyle & Cardiovascular Health: Smoking cessation, heart-healthy nutrition, regular exercise, and UV protection are vital to slowing degenerative retinal breakdown.
● Regular Monitoring: Using tools like the Amsler grid at home and scheduling regular retinal imaging ensures that any rapid progression toward wet AMD or advanced atrophy is caught early.
Whatever path you’re considering, if your vision isn’t what it used to be and you want to hear more about what options might work for you, schedule an appointment to see our world-class eye doctors in Midlothian, Texas today.
Book a Visit
At Texas Eye and Cataract, we know how important it is to see life with clear vision. We understand that being your best means seeing your best.
At Texas Eye and Cataract, we know how important it is to see life with clear vision. We understand that being your best means seeing your best.
